Immunoconjugate Therapy of Hematologic Malignancies, Softcover reprint of the original 1st ed. 1993 Cancer Treatment and Research Series, Vol. 68

Provides an update of a rapidly advancing field. So far, immunoconjugates have mostly been reserved for patients with advanced refractory disease. However, it is anticipated that in future these reagents will be utilized as a complement to traditional therapy of haemolytic malignancies.

1. Radioimmunotherapy of lymphoma.- 2. High-dose radioimmunotherapy of lymphomas.- 3. Treatment of leukemia with radiolabeled monoclonal antibodies.- 4. Imaging and dosimetry determinations using radiolabeled antibodies.- 5. New approaches to radiolabeling monoclonal antibodies.- 6. Immunotoxin therapy of lymphoma.- 7. Immunotoxins for the therapy for graft versus host disease.- 8. Recombinant fusion toxins — A new class of targeted biologic therapeutics.- 9. Chimeric antibodies for the treatment of hematologic malignancy.- 10. Use of bispecific autibodies in the therapy of tumors.